Metyrapone is used for the medical control of hypercortisolism in Cushing's syndrome (ACTH dependent or independent). The aim for medical treatment is to achieve pre-operative control of hypercortisolism, or for control of residual disease persisting post-operatively (TSS, adrenalectomy). It is not for long term definitive treatment/cure, only as an adjunct (surgery is the aim for cure in most causes of Cushing's syndrome). Metyrapone hence acts by inhibiting adrenal steroidogenesis. One side effect is hirsutism (in women) because of the excess androgen precursors created. The other commonly used agent for medical treatment of Cushing's is ketoconazole (an anti-fungal agent). This does not exhibit the side effect of hirsutism.
Causes of shortness of breath include asthma , bronchitis , pneumonia , pneumothorax , anemia , lung cancer , inhalation injury, pulmonary embolism , anxiety , COPD , high altitude with lower oxygen levels, congestive heart failure , arrhythmia , allergic reaction , anaphylaxis , subglottic stenosis, interstitial lung disease , obesity , tuberculosis , epiglottitis, emphysema , pulmonary fibrosis , pulmonary artery hypertension , pleurisy , croup , polymyositis , Guillain-Barré syndrome , sarcoidosis , rib fracture, carbon monoxide poisoning, obesity, and aerobic exercise .